Monday November 23 2009 | Biotechnology feed | All feeds
|
|
Myelos Corporation
Download detailed PDF Members: Myelos’ unique, patented technology has permitted the rapid development of the company’s lead compound, Prosaptide™ TX14(A), from pre-clinical studies into Phase 2 clinical trials. The breadth of the technology platform and the "blueprint" afforded by the success of Prosaptide™ TX14(A) have provided the foundation for the development of other future therapeutics for a variety of degenerative diseases.
This page has been viewed 1058 times since April 2007, the link to the organisation's website has been followed 224 times Recent Search Terms used to find this page: Myelos Corporation | Myelos Corporation | myelos.net | myelos | myelos corporation | myelos corporation | myelos net productos download | myelos net productos download | myelos | Myelos corporation | . Search for more companies in San Diego, Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Myelos Corporation | |||||||||||||||||||||||||||||||||||||||||||
|